Our
Facilities

NorthStar’s corporate headquarters in Beloit house our executive, administrative, Quality Affairs/Regulatory Affairs, logistics and Copper-67 (Cu-67) production activities, customer care, and training teams.

This 20,000 sq ft facility, completed in September 2019, is equipped with a chemical processing line, analytical testing and metallurgy laboratories, and radioactive storage. Regular production runs of Radiochemical Grade (RCG) Copper-67 (Cu-67) are conducted here. Currently, the building is undergoing a major infrastructure upgrade, including the addition of new processing lines and product hot cells. Additionally, work is in progress to retrofit previously installed hot cells, originally dedicated to the production of other isotopes, to enhance our Cu-67 output. These upgrades are part of our strategy to upscale processes and prepare for large-scale cGMP commercial production. Furthermore, this facility includes a cGMP-compliant CDMO suite for final dose products.

Groundbreaking for this 30,000 sq. ft. facility took place in September 2019, and construction was completed in January 2021. The first pair of electron beam accelerators are operational and producing Cu-67 on a routine basis.

NorthStar’s unique and proprietary electron accelerator production facility and processes are designed to optimize efficiency throughout the production cycle. This setup allows us the flexibility to produce batches of various sizes based on market demand.

During the initial construction, site preparation was completed adjacent to the first building, allowing NorthStar to swiftly add up to three additional mirror-image accelerator facilities. These new facilities are planned to support the growing market demand for Cu-67 and other radioisotopes.

Groundbreaking for this 30,000+ sq ft first-of-its-kind Actinium-225 (Ac-225) Production facility, dedicated exclusively to commercial-scale production of non-carrier added (n.c.a.) Ac-225, was celebrated in September 2021. The facility houses a Rhodotron® TT300 HE electron beam accelerator used solely for the production of Ac-225. This marks the third electron accelerator NorthStar has purchased from IBA. Utilizing design concepts and key learnings from our Mo-99 and Cu-67 programs, this facility will allow for more efficient and expedited completion timelines, with potential future expansion plans in mind.

Construction began in early 2022 with initial production of radiochemical grade Ac-225 planned for 2025. We expect submission of the Drug Master File to the U.S. Food and Drug Administration (U.S. FDA) in 2025.

NorthStar Medical Radioisotopes will be the first and only U.S. company housing world class, commercial-scale, multi-radioisotope production and radiopharmaceutical development services on one campus. Our new Radiopharmaceutical CDMO facility is located on our 55-acre campus in Beloit, Wisconsin, enabling collaborator companies to realize the logistical, regulatory and other efficiency benefits afforded by a single site location.

Groundbreaking for the new 52,000 sq ft, state-of-the-art Radiopharmaceutical CDMO facility occurred in November 2022. The facility is purpose-engineered to meet growing demands for therapeutic and diagnostic radiopharmaceuticals. Also designed with the needs of our partner companies in mind, the facility will offer the flexibility needed to support advancement of their products, from development to commercialization.

NorthStar’s 55-acre Beloit campus has space for additional facilities that will support the production of other isotopes and related products as their development progresses.